APA (7th ed.) Citation

Panuganti, V. K., Alluri, C. V., Dundigalla, M. R., Mohammad, J., Madala, P. K., & K. S. S. V. V., S. (2025). Safety, Tolerability, and Pharmacokinetics of NorUrsodeoxycholic Acid (Shilpa Medicare Limited, India) in Healthy Adults: Results From a Phase I Open‐Label Dose‐Escalation Study. Advances in pharmacological and pharmaceutical sciences, 2025(1), 6613969. https://doi.org/10.1155/adpp/6613969

Chicago Style (17th ed.) Citation

Panuganti, Veerendra Kumar, Chandrasekhar Varma Alluri, Mamatha Reddy Dundigalla, Javeed Mohammad, Pavan Kumar Madala, and Sanyasirao K. S. S. V. V. "Safety, Tolerability, and Pharmacokinetics of NorUrsodeoxycholic Acid (Shilpa Medicare Limited, India) in Healthy Adults: Results From a Phase I Open‐Label Dose‐Escalation Study." Advances in Pharmacological and Pharmaceutical Sciences 2025, no. 1 (2025): 6613969. https://doi.org/10.1155/adpp/6613969.

MLA (9th ed.) Citation

Panuganti, Veerendra Kumar, et al. "Safety, Tolerability, and Pharmacokinetics of NorUrsodeoxycholic Acid (Shilpa Medicare Limited, India) in Healthy Adults: Results From a Phase I Open‐Label Dose‐Escalation Study." Advances in Pharmacological and Pharmaceutical Sciences, vol. 2025, no. 1, 2025, p. 6613969, https://doi.org/10.1155/adpp/6613969.